Research Article

Capacity Evaluation of Diagnostic Tests For COVID-19 Using Multicriteria Decision-Making Techniques

Table 3

Weighted normalized data of the SARS-CoV-2 diagnostic tests.

CriteriaImportance weightMax/MinNaso/oropharyngeal swab PCRCell cultureCoV-19 antigen detectionCoV-19 antibody IgMCoV-19 antibody IgGChest X-rayChest CT

No symptom-window periodVHMax0.470.470.470.160.160.160.32
Early stageVHMax0.470.470.470.470.160.160.47
Active phaseVHMax0.470.470.470.470.470.160.47
Recurrent stageVHMax0.160.160.160.160.470.320.47
Past infectionMMax0.090.090.090.090.260.170.26
Recovery stageLMax0.040.040.040.090.130.040.13
CostMMin0.090.090.260.090.090.090.09
AccessibilityVHMax0.470.160.160.470.470.470.47
UsabilityMMax0.260.090.260.260.260.260.26
EquipmentMMax0.170.090.260.090.090.090.26
EducationMMax0.170.090.090.260.260.170.26
SensitivityHMax0.130.390.130.130.130.260.39
SpecificityHMax0.390.390.130.260.260.260.39
False positivityVHMin0.160.160.470.470.470.470.47
False negativityVHMin0.470.160.470.470.470.470.47

VH: very high; H: high; M: medium; L: low.